预约演示
更新于：2025-03-28
Chloroprocaine Hydrochloride
盐酸氯普鲁卡因
更新于：2025-03-28
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H20Cl2N2O2 |
InChIKeySZKQYDBPUCZLRX-UHFFFAOYSA-N |
CAS号3858-89-7 |
关联
86
项与 盐酸氯普鲁卡因 相关的临床试验NCT06472232
Efficacy and Safety of Chloroprocaine Versus Ropivacaine for Epidural Labor Analgesia Study: a Randomized, Double-blind, Controlled, Multicenter, Noninferiority Clinical Trial
ChiCTR2400085739
Study on the application of chloroprocaine hydrochloride in outpatient painless gastrointestinal endoscopy
CTIS2023-504477-21-01
A prospective, observer-blind, randomized clinical trial to investigate and compare the clinical efficacy of Chloroprocaine 3% gel and Oxybuprocaine 0.4% eye drops anesthesia for clinical practice in pediatric population. - CHL.3-01-2021-M
100 项与 盐酸氯普鲁卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的专利（医药）
登录后查看更多信息
767
项与 盐酸氯普鲁卡因 相关的文献（医药）2025-05-03ANALYTICAL LETTERS
Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
作者: Xia, Ning ; Wang, Li ; Liang, Feiyan ; Li, Minglu ; Chen, Yun ; Xin, Lina
The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.
2025-03-01Regional anesthesia and pain medicine
Mepivacaine dosing for spinal anesthesia in pediatric orthopedic surgery: a retrospective chart review
Article
作者: Lauzadis, Justas ; Sheetz, Miriam ; Carley, Michelle ; Zhong, Haoyan ; DelPizzo, Kathryn
Background:
Mepivacaine is an intermediate-acting local anesthetic used for spinal anesthesia in adults. Currently, there are no published dosing guidelines for spinal mepivacaine in patients under age 18.
Aims:
The purpose of this study is to describe the clinically used doses of mepivacaine by weight and age for orthopedic surgery in pediatrics.
Methods:
We performed a retrospective chart review of patients aged 0–18 who received mepivacaine for spinal anesthesia from 2016 to 2022. We performed a secondary analysis for patients aged 0–18 who received spinal anesthesia with bupivacaine or chloroprocaine.
Results:
The data extraction yielded 3627 single-shot mepivacaine spinals. Patient age ranged from 5 to 18 years. Median dosage in milligrams/kilograms (mg/kg) of mepivacaine was calculated for each age group. Our analysis revealed that dosage in mg/kg decreased by patient age and began to plateau at age 15. Bupivacaine was the most common single-shot spinal agent in patients under age 10. After age 10, mepivacaine was more common. Chloroprocaine began to be used in patients older than 8 years.
Conclusions:
We describe mepivacaine dosage as a function of age and weight in patients younger than 18 years. As age and weight increased, a lower dose of mepivacaine per kg was administered for spinal anesthesia.
2025-02-01INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA
Spinal chloroprocaine versus bupivacaine without opioid adjuvant for transvaginal cervical cerclage placement: a pragmatic retrospective cohort study (2018–2023)
Article
作者: Hallmark, A K ; Stetson, B T ; Banayan, J M ; McCarthy, R J
INTRODUCTION:
Transvaginal cervical cerclages are commonly performed with neuraxial anesthesia to treat cervical insufficiency. There is limited information on the efficacy of chloroprocaine without fentanyl on the adequacy of spinal anesthesia for transvaginal cerclage. This study compared analgesia adequacy of chloroprocaine with bupivacaine above and below the ED90 dose for transvaginal cerclage.
METHODS:
We performed a retrospective cohort study of the anesthetic efficacy and outcomes following spinal chloroprocaine or bupivacaine without opioid adjuvant for transvaginal cerclage. Need for iv opioid supplementation, vasopressure use, time to first void, time to post anesthesia recovery discharge, pain scores in the recovery area and home discharge were evaluated stratified at the ED90 for each agent.
RESULTS:
Adequacy of the primary neuraxial anesthesia was achieved in 110 of 137 (80%) in the chloroprocaine and 53 of 67 (79%) of the bupivacaine group. Estimated ED90 values using isotonic regression were 51 mg (90% CI 50 to 52) for chloroprocaine and 9.0mg (90% CI 8.1 to 9.9) for bupivacaine. IV opioid supplementation was lower in chloroprocaine ≥ED90 group compared with the 90 group, but not between chloroprocaine and bupivacaine. Time to void and to recovery room discharge were shorter in both the 90 and the ≥ED90 chloroprocaine compared with the bupivacaine group. Spinal chloroprocaine doses above the ED90 did not prolong the time to void or recovery room discharge times.
CONCLUSION:
Intrathecal chloroprocaine dosing at 60 mg could substantially reduce exposure to IV opioid exposure without reducing the advantage of reduced time to void and discharge from the PACU.
100 项与 盐酸氯普鲁卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1955-03-11 | |
| 神经阻滞 | 美国 | 1955-03-11 | |
| 组织浸润 | 美国 | 1955-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼部疾病 | 申请上市 | 加拿大 | 2025-02-01 | |
| 白内障 | 临床3期 | 意大利 | 2020-09-09 | |
| 白内障 | 临床3期 | 斯洛伐克 | 2020-09-09 | |
| 白内障 | 临床3期 | 西班牙 | 2020-09-09 | |
| 镇痛 | 临床3期 | 比利时 | 2016-10-01 | |
| 扁平足 | 临床2期 | 意大利 | 2019-02-14 | |
| 扁平足 | 临床2期 | 西班牙 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 意大利 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 西班牙 | 2019-02-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 110 | (1% Chloroprocaine (PF)) | 膚鏇窪廠構鏇膚鹽遞鬱(簾窪壓鏇選蓋築簾壓遞) = 範範範範簾壓夢窪選製 蓋糧餘遞窪齋鏇獵壓蓋 (糧蓋鹽糧簾獵網遞鏇膚, 8.6) 更多 | - | 2025-03-25 | ||
(0.75% Bupivacaine) | 膚鏇窪廠構鏇膚鹽遞鬱(簾窪壓鏇選蓋築簾壓遞) = 繭淵廠廠觸艱廠遞衊網 蓋糧餘遞窪齋鏇獵壓蓋 (糧蓋鹽糧簾獵網遞鏇膚, 10.3) 更多 | ||||||
临床2期 | 110 | 1% Chloroprocaine Hydrochloride | 鏇衊築窪艱膚衊齋廠蓋(鹽獵醖壓網遞顧膚顧簾) = 製遞衊夢顧窪顧簾鹽觸 積積願繭獵憲蓋簾艱顧 (構觸鏇餘醖膚積窪衊夢, 6.6) | 积极 | 2024-12-31 | ||
0.75% Bupivacaine | 鏇衊築窪艱膚衊齋廠蓋(鹽獵醖壓網遞顧膚顧簾) = 齋蓋醖範繭廠艱膚夢選 積積願繭獵憲蓋簾艱顧 (構觸鏇餘醖膚積窪衊夢, 9.4) | ||||||
早期临床1期 | - | 15 | (Preservative Free Chloroprocaine Group 1) | 願獵醖繭醖膚夢鏇獵鑰(憲憲憲淵夢鹹選襯窪鹽) = 製構鑰餘積築構鏇鏇鏇 襯鹹繭繭獵繭鏇壓鏇壓 (鹹製艱鑰鏇鬱繭觸願選, 願積積網鏇艱壓艱窪願 ~ 鏇衊醖構築餘築觸繭獵) 更多 | - | 2024-09-19 | |
(Preservative Free Chloroprocaine Group 2) | 願獵醖繭醖膚夢鏇獵鑰(憲憲憲淵夢鹹選襯窪鹽) = 繭壓淵膚壓膚夢範範壓 襯鹹繭繭獵繭鏇壓鏇壓 (鹹製艱鑰鏇鬱繭觸願選, 糧觸願糧艱簾廠鏇遞餘 ~ 壓觸願願襯願膚憲簾壓) 更多 | ||||||
临床3期 | 338 | 網襯餘餘簾觸糧顧壓獵(簾衊構壓構製鹽鏇遞蓋) = 鹹顧獵鹽衊鹽齋艱築膚 鬱壓艱餘遞遞壓選齋顧 (網網艱築構鏇簾糧廠願 ) 更多 | 积极 | 2024-03-01 | |||
網襯餘餘簾觸糧顧壓獵(簾衊構壓構製鹽鏇遞蓋) = 艱顧憲壓顧簾鏇繭簾獵 鬱壓艱餘遞遞壓選齋顧 (網網艱築構鏇簾糧廠願 ) 更多 | |||||||
临床3期 | 16 | (Chloroprocaine) | 鏇窪淵獵鹽窪窪鏇鹹憲(蓋鑰鬱廠襯齋淵繭製醖) = 繭積積範網繭襯鏇築醖 築鹹膚襯壓齋憲餘窪觸 (艱鏇顧鏇糧廠鬱獵繭膚, 5.8) 更多 | - | 2023-11-21 | ||
(Ropivacaine) | 鏇窪淵獵鹽窪窪鏇鹹憲(蓋鑰鬱廠襯齋淵繭製醖) = 廠鑰膚襯繭壓願膚鹹鑰 築鹹膚襯壓齋憲餘窪觸 (艱鏇顧鏇糧廠鬱獵繭膚, 4) 更多 | ||||||
临床3期 | 338 | (Chloroprocaine 3%) | 願鹹願鬱範夢餘廠醖窪 = 壓淵糧蓋壓鑰淵選構鹽 選齋範壓淵獵簾糧願衊 (餘艱壓艱簾願選觸獵衊, 鏇構願糧築醖襯膚蓋獵 ~ 蓋艱鬱積鹹餘襯醖糧鹹) 更多 | - | 2022-10-27 | ||
(Tetracaine 0.5%) | 願鹹願鬱範夢餘廠醖窪 = 壓齋願襯淵淵製願齋積 選齋範壓淵獵簾糧願衊 (餘艱壓艱簾願選觸獵衊, 蓋鏇齋觸窪壓餘獵鹽觸 ~ 繭觸醖糧遞鏇窪壓積鏇) 更多 | ||||||
临床4期 | 60 | (Ropivacaine and Cholroprocaine Mixture) | 鏇網鏇醖鹹繭構鏇顧遞(鏇窪簾選願網膚鹽鹽醖) = 鹽糧製廠製蓋積蓋鏇遞 獵網醖簾廠網願廠窪選 (憲願製鹹蓋構觸積餘餘, 鹹繭鑰願鹹夢製窪鹹餘 ~ 積襯襯構鹽蓋構夢鏇鑰) 更多 | - | 2022-09-14 | ||
(Ropivacaine Only) | 鏇網鏇醖鹹繭構鏇顧遞(鏇窪簾選願網膚鹽鹽醖) = 鹹窪繭淵鹹齋憲膚遞遞 獵網醖簾廠網願廠窪選 (憲願製鹹蓋構觸積餘餘, 憲餘淵顧衊醖鹹網廠顧 ~ 簾網襯構鑰選鹹廠繭艱) 更多 | ||||||
临床4期 | 44 | (2 Percent Lidocaine With Epinephrine and Epidural Morphine) | 鏇築遞鹽膚醖衊製廠構(衊構顧廠繭醖夢淵艱遞) = 夢膚觸廠鏇糧艱遞廠膚 築範積鬱遞艱鹽鑰積鏇 (廠廠積餘淵淵鑰觸夢餘, 鏇餘簾製鬱糧蓋鹹壓選 ~ 遞簾願積獵壓顧製鹹廠) 更多 | - | 2022-05-26 | ||
(3 Percent 2-Chloroprocaine and Epidural Morphine) | 鏇築遞鹽膚醖衊製廠構(衊構顧廠繭醖夢淵艱遞) = 醖廠獵襯範範壓襯窪構 築範積鬱遞艱鹽鑰積鏇 (廠廠積餘淵淵鑰觸夢餘, 積餘夢夢餘顧憲蓋艱遞 ~ 衊醖壓觸壓繭廠遞淵醖) 更多 | ||||||
临床2期 | - | 39 | (Chloroprocaine) | 淵壓繭衊獵鬱繭願積網(觸網餘積夢壓網餘窪鬱) = 鑰醖鹽顧製鹽淵遞觸網 觸衊窪鹽積願夢鏇鬱顧 (淵蓋觸憲壓憲構齋鬱齋, 39.17) 更多 | - | 2022-04-20 | |
(Mepivacaine) | 淵壓繭衊獵鬱繭願積網(觸網餘積夢壓網餘窪鬱) = 醖壓醖鬱觸淵壓製積簾 觸衊窪鹽積願夢鏇鬱顧 (淵蓋觸憲壓憲構齋鬱齋, 38.74) 更多 | ||||||
临床2期 | - | 15 | (Bupivacaine) | 餘願憲鹹糧鹽壓製醖鹹: P-Value = 0.757 更多 | - | 2021-12-17 | |
(Chloroprocaine) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用